% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{MargolinMiller:124434,
      author       = {Y. Margolin-Miller and N. Yanichkin and K. Shichrur and H.
                      Toledano and A. Ohali and T. Tzaridis$^*$ and S. Michowitz
                      and S. Fichman-Horn and M. Feinmesser and S. Pfister$^*$ and
                      H. Witt$^*$ and U. Tabori and E. Bouffet and V. Ramaswamy
                      and C. Hawkins and M. D. Taylor and I. Yaniv and S. Avigad},
      title        = {{P}rognostic relevance of mi{R}-124-3p and its target
                      {TP}53{INP}1 in pediatric ependymoma.},
      journal      = {Genes, chromosomes $\&$ cancer},
      volume       = {56},
      number       = {8},
      issn         = {1045-2257},
      address      = {New York, NY},
      publisher    = {Wiley-Liss},
      reportid     = {DKFZ-2017-01311},
      pages        = {639 - 650},
      year         = {2017},
      abstract     = {Ependymoma is a malignant pediatric brain tumor, often
                      incurable under the current treatment regimen. We aimed to
                      evaluate the expression of microRNAs (miRs) in pediatric
                      ependymoma tumors in an attempt to identify prognostic
                      molecular markers which would lead to potential therapeutic
                      targets. Following miR-array expression analysis, we focused
                      on 9 miRs that correlated with relapse which were further
                      validated by quantitative real-time PCR (qRT-PCR) in a
                      cohort of 67 patients. Western blotting and
                      immunohistochemistry were used to measure target protein
                      expression in 20 and 34 tumor samples, respectively. High
                      expression of miR-124-3p significantly correlated with the
                      lower progression-free survival (PFS) of $16\%$ compared to
                      $67\%$ in those expressing low levels (P = .002).
                      Interestingly, in the group of patients with local disease
                      (n = 56) expression levels of this miR distinguished 2
                      subgroups with a significantly different outcome
                      (P = .001). miR-124-3p was identified as an independent
                      prognostic factor of relapse in the multivariate analysis
                      performed in the whole cohort and in the group with
                      localized disease. In the localized group, a patient
                      expressing high levels of miR-124-3p had a 4.1-fold
                      increased risk for relapse (P = .005). We demonstrated
                      the direct binding of miR-124-3p to its target TP53INP1.
                      Negative TP53INP1 protein levels correlated with a poor
                      outcome (P = .034). We propose miR-124-3p and TP53INP1
                      as new biomarkers for prognostic stratification that may be
                      possible therapeutic targets for ependymoma.},
      cin          = {B062},
      ddc          = {570},
      cid          = {I:(DE-He78)B062-20160331},
      pnm          = {312 - Functional and structural genomics (POF3-312)},
      pid          = {G:(DE-HGF)POF3-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:28437838},
      doi          = {10.1002/gcc.22467},
      url          = {https://inrepo02.dkfz.de/record/124434},
}